Key result
Systemic inflammation drives concurrent atherosclerosis and osteoporosis, supporting treat-to-target suppression in rheumatic disease.
Answers are grounded in this paper and cite their sources.
Cardiovascular (CV) disease and osteoporosis (OP) have become increasing challenges in the aging population and even more in patients with inflammatory rheumatic diseases, such as rheumatoid arthritis, spondyloarthropathies, and systemic lupus erythematosus. In this review, we discuss how the epidemiology and pathogenesis of CV events and OP are overlapping. Smoking, diabetes mellitus, physical inactivity as conventional risk factors as well as systemic inflammation are among the modifiable risk factors for both CV events and bone loss. In rheumatic patients, systemic "high-grade" inflammation may be the primary driver of accelerated atherogenesis and bone resorption. In the general population, in which some individuals might have low-grade systemic inflammation, a holistic approach to drug treatment and lifestyle modifications may have beneficial effects on the bone as well as the vasculature. In rheumatic patients with accelerated inflammatory atherosclerosis and bone loss, the rapid and effective suppression of inflammation in a treat-to-target regime, aiming at clinical remission, is necessary to effectively control comorbidities.
No takes yet. Share an insight, caveat, or question.
Szekanecz et al. (2019) conducted a review in Atherosclerosis and osteoporosis (particularly in inflammatory rheumatic diseases). Holistic drug treatment, lifestyle modifications, and treat-to-target suppression of inflammation was evaluated. Systemic inflammation and shared risk factors drive both atherosclerosis and osteoporosis, requiring holistic care and treat-to-target inflammation suppression in rheumatic patients.
Synapse has enriched 10 related papers. Consider them for comparative context: